KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Net Margin (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Net Margin for 11 consecutive years, with 867.29% as the latest value for Q1 2025.

  • On a quarterly basis, Net Margin changed N/A to 867.29% in Q1 2025 year-over-year; TTM through Dec 2025 was 4612.13%, a N/A change, with the full-year FY2025 number at 4612.13%, changed N/A from a year prior.
  • Net Margin was 867.29% for Q1 2025 at Xenon Pharmaceuticals, up from 28143.94% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 220.98% in Q1 2022 to a low of 28143.94% in Q3 2022.
  • A 3-year average of 4672.1% and a median of 769.17% in 2021 define the central range for Net Margin.
  • Biggest YoY gain for Net Margin was 13104bps in 2022; the steepest drop was -2780876bps in 2022.
  • Xenon Pharmaceuticals' Net Margin stood at 671.05% in 2021, then crashed by -4094bps to 28143.94% in 2022, then surged by 97bps to 867.29% in 2025.
  • Per Business Quant, the three most recent readings for XENE's Net Margin are 867.29% (Q1 2025), 28143.94% (Q3 2022), and 5813.06% (Q2 2022).